Mutations in BRCA1 and BRCA2, which are present in about 2.5% of the Ashkenazi Jewish population, have been associated with an increased risk of breast and ovarian cancer, but it is unclear whether these mutations also increase the risk of colorectal cancer. Some studies have suggested an increased risk of colorectal cancer among mutation carriers, whereas other studies have found no such association. Current nationally recognized guidelines recommend that all BRCA1/2 mutation carriers be informed that they may be at an increased risk for colorectal cancer.
Tomas Kirchhoff, Ph.D., Kenneth Offit, M.D., and their colleagues at the Memorial Sloan-Kettering Cancer Center in New York compared the incidence of BRCA1/2 mutations in 586 Ashkenazi Jewish patients with colorectal cancer with that of 5,012 patients without a known history of colorectal cancer. The authors found no association between the presence of a BRCA mutation and risk of colorectal cancer.
In a second study, Bethany L. Niell and Stephen B. Gruber, M.D., Ph.D., of the University of Michigan, Ann Arbor, and their colleagues performed genetic testing on 1,422 patients with colorectal cancer and 1,566 control subjects without colorectal cancer in a population-based study in Israel. They also found no association between the presence of a BRCA mutation and the risk of colorectal cancer.
A family history of breast cancer in a female relative was not associated with an increased risk of colorectal cancer, even after adjusting for the presence of a BRCA founder mutation. The authors conclude that Ashkenazi BRCA founder mutations do not confer a strongly elevated risk of colorectal cancer. Similarly, a family history of breast cancer does not appear to be a strong risk factor for colorectal cancer in this population.
In an accompanying editorial, Judy E. Garber, M.D., and Sapna Syngal, M.D., of the Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, ask, "These studies were certainly well done, but are they the final words on the subject? It depends on the exact question one is trying to answer." They note that a future study may find an increased risk of colorectal cancer among BRCA1/2 mutation carriers, but the current studies indicate that it will be a small increase at most, or limited to a particular subset of mutation carriers. "Intensified targeted colorectal cancer screening and prevention should be directed only to the subset of BRCA mutation carriers who have remarkable personal or family colorectal cancer history or other risk factors."
• Sally Pobojewski, University of Michigan, 734-764-2220; firstname.lastname@example.org.
• Joanne Nicholas, Memorial Sloan-Kettering Cancer Center, 212-639-3573; email@example.com.
• Editorial: William Schaller, Dana-Farber Cancer Institute, 617-632-5357, firstname.lastname@example.org.
Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 2003;96:15-21.
Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 2003;96:68-70.
Editorial: Garber JE, Syngal S. One less thing to worry about: The shrinking spectrum of tumors in BRCA founder mutation carriers. J Natl Cancer Inst 2003;96:2-3.
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.